Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes

NCT03222856 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Eribulin

Sponsor

MedSIR